Drug Trial Radar · NCT06717126
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Feb 27, 2025
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- iOncturaIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma. The main questions it aims to answer are: Does roginolisib extend overall survival compared to standard treatment? How does dosing of roginolisib impact quality of life compared to standard treatment?
Conditions
- Uveal Melanoma
- Ocular Melanoma
Interventions
roginolisibDrug
rognolisib
Investigator choice of standard therapyDrug
Investigator will choose the most appropriate treatment standardly given to patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: Patients will be followed up for overall survival every 12 weeks, for 96 weeks from last patient enrolled, until their death or end of the study
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
SSD Tumori Rari e Melanoma Viale Orazio Flacco
Bari, Italy
IRCSS National Cancer Institute, "G.Pascale" Foundation Dip. CORP-S di Ricerca ed Assistenziale Cute, Melanoma lmmunologia Oncologica Sperimentale e Terapie Innovative
Naples, Italy
IRCSS Istituto Oncologico Veneto UOS Oncologia 2 del Melanoma Ospedale Busonera
Padova, Italy
IRCCS Istituto Clinico Humanitas
Rozzano, Italy
A.O.U.S. Santa Maria delle Scotte
Siena, Italy
Institut Catala d'Oncologia - ICO L'Hospitalet
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Complejo Hospitalario Universitario de Santiago - CHUS
Santiago de Compostela, Spain
Hospital Universitario Virgen Macarena, University of Seville
Seville, Spain
Consorcio Hospital General Universitario de València - CHGUV
Valencia, Spain
Beatson West of Scotland Cancer Centre, Glasgow (NHS Greater Glasgow & Clyde)
Glasgow, United Kingdom
University College London Hospital NHS
London, United Kingdom
Royal Marsden Hospital
London, United Kingdom
University Hospital Southampton NHS Foundation
Southampton, United Kingdom
East and North Hertfordshire NHS Trust (Mount Vernon Cancer Centre)
Northwood, Middlesex, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Wirral, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.